Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3BP5 antisense RNA 1 (SH3BP5-AS1)
- Target
- SH3BP5-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other (not a classical receptor, enzyme, transporter, etc.)
01
Overview
SH3BP5 antisense RNA 1 (SH3BP5-AS1) is a long non-coding RNA, transcribed antisense to the SH3BP5 gene on chromosome 3. It is upregulated in pancreatic cancer and associated with resistance to gemcitabine chemotherapy, poor prognosis, and increased malignancy. SH3BP5-AS1 acts as a competing endogenous RNA, sponging microRNAs (notably miR-139-5p), and upregulates CTBP1 to activate the Wnt signaling pathway. Its expression is regulated through N6-methyladenosine (m6A) RNA modifications. SH3BP5-AS1 is being explored as both a biomarker and a potential therapeutic target in oncology.
- Other names
- SH3BP5-AS1SH3BP5 AS1SAB antisense RNA 1
02
Mechanism of action
Drugs affecting SH3BP5-AS1 would suppress its expression or disrupt its ceRNA activity to restore sensitivity to gemcitabine (mechanism primarily by inhibiting its sponge activity for miR-139-5p and downstream Wnt pathway activation)
03
Biological functions
Regulation of gene expression (acts as a competing endogenous RNA/ceRNA)Modulation of drug resistance mechanisms (notably gemcitabine resistance in pancreatic cancer)Activation of Wnt signaling pathwaySponge for microRNAs, particularly miR-139-5pRegulation of cell migration, invasion, tumorigenicity
04
Disease associations
Cancer (pancreatic cancer: associated with increased malignancy, drug resistance, worse prognosis)Potential role in other cancers (not yet fully characterized)
05
Safety considerations
As a non-coding RNA involved in regulating multiple signaling pathways, off-target effects and broad impact on gene regulation are potential concerns for therapeutic interventions
06
Interacting drugs
Gemcitabine (GEM)
07
Biomarkers
SH3BP5-AS1 expression levels (proposed as a prognostic biomarker for pancreatic cancer and gemcitabine responsiveness)
Beyond the preview
Go deeper on SH3BP5 antisense RNA 1 (SH3BP5-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH3BP5 antisense RNA 1 (SH3BP5-AS1).